Form 4 for FDMT 4D Molecular Therapeutics, Inc.
Accepted 2024-01-25 00:00:00 ET · period of report 2024-01-23 · accession 0000950170-24-007477 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-01-25 | 2024-01-23 | FDMT | Kirn David | CEO, Dir | S - Sale | $18.41 | -5,696 | 1.15M | -0.5% | -$104.9K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-01-23 | S | D | 5,696 | $18.41 | 1,151,154 | D | — | — | (F2) The transaction was executed in multiple trades in prices ranging from $18.06 to $18.76, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. |